Results 11 to 20 of about 51,359 (234)

Efficacy and safety of SGLT2 inhibitor on insulin resistance and hyperglycemia in Werner syndrome-A case report. [PDF]

J Diabetes Investig
Dapagliflozin improved glycemic control and insulin resistance while preserving skeletal muscle mass, body weight, and renal function over 2 years in a patient with Werner syndrome. These findings suggest that SGLT2 inhibitors may be used safely with beneficial effects in patients with Werner syndrome.
Yagi T, Aotani D, Hasegawa C, Shimizu Y, Koyama H, Maezawa Y, Yokote K, Tanaka T.   +7 more
europepmc   +2 more sources

Post-authorisation Safety Study of Pioglitazone Use and Safety Endpoints of Interest in Denmark After Direct Healthcare Professional Communication

Drugs - Real World Outcomes, 2019
Introduction A Direct Healthcare Professional Communication (DHPC) sent in Denmark on 11 August 2011 provided information on new pioglitazone labelling and guidance on monitoring treatment effectiveness.
Javier Cid Ruzafa, Sinna Pilgaard Ulrichsen, Dimitri Bennett, Vera Ehrenstein   +3 more
doaj   +1 more source

A retrospective study to assess the risk of bladder cancer in type-2 diabetic patients treated with pioglitazone

Perspectives in Clinical Research, 2021
Introduction: Pioglitazone has been a cornerstone of oral hypoglycemic therapy. Concerns have been raised about its association with urinary bladder cancer.
Prabhat Agrawal, Apoorva Jain, Ashish Gautam, Ashwini Kumar Nigam, Nikhil Pursnani, Maaz Farooqui   +5 more
doaj   +1 more source

Pioglitazone inhibits growth of carcinoid cells and promotes TRAIL-induced apoptosis by induction of p21(waf1/cip1) [PDF]

, 2001
Background/Aims: We investigated the effect of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist pioglitazone on growth and TRAIL-induced apoptosis in carcinoid cells.
Chen, Youhai, El-Deiry, Wafik S., Göke, Alexandra, Göke, Burkhard, Göke, Rüdiger   +4 more
core   +1 more source

Fish oil prevents excessive accumulation of subcutaneous fat caused by an adverse effect of pioglitazone treatment and positively changes adipocytes in KK mice

Toxicology Reports, 2016
Pioglitazone, a thiazolidinedione (TZD), is widely used as an insulin sensitizer in the treatment of type 2 diabetes. However, body weight gain is frequently observed in TZD-treated patients. Fish oil improves lipid metabolism dysfunction and obesity. In
Yuzuru Iizuka, Hyounju Kim, Maki Nakasatomi, Takuya Izawa, Satoshi Hirako, Akiyo Matsumoto   +5 more
doaj   +1 more source

Pioglitazone Prevents Capillary Rarefaction in Streptozotocin-Diabetic Rats Independently of Glucose Control and Vascular Endothelial Growth Factor Expression [PDF]

, 2012
Background/Aims: Reduction of capillary network density occurs early in the development of metabolic syndrome and may be relevant for the precipitation of diabetes.
Andreas Dendorfer, Arany Z, Astrid Ashoff, Baraka A, Battegay EJ, Billiet L, Biscetti F, Blasi ER, Chintalgattu V, Cipolla MJ, Dendorfer A, Duan SZ, Emanueli C, Emoto M, Fatimunnisa Qadri, Frisbee JC, Frisbee JC, Frisbee JC, Gealekman O, Geraldes P, Goodwill AG, Han B, Heidbreder M, Kobayashi N, Levy BI, Lillioja S, Lindenmeyer MT, Nishikawa T, Noon JP, Ohga S, Olaf Jöhren, Polikandriotis JA, Prewitt RL, Redondo S, Reinhard Eggers, Romeo G, Son NH, Thangarajah H, Vogt CJ, Walter Raasch, Weidner N, Yue Tl TL, Zolk O   +42 more
core   +1 more source

Telomere length as a predictor of response to Pioglitazone in patients with unremitted depression: a preliminary study. [PDF]

, 2016
We studied peripheral leukocyte telomere length (LTL) as a predictor of antidepressant response to PPAR-γ agonist in patients with unremitted depression.
Blackburn, E, Epel, E, Lin, J, Lin, KW, Rasgon, N   +4 more
core   +1 more source

Bladder-cancer-associated mutations in RXRA activate peroxisome proliferator-activated receptors to drive urothelial proliferation [PDF]

, 2017
RXRA regulates transcription as part of a heterodimer with 14 other nuclear receptors, including the peroxisome proliferator-activated receptors (PPARs).
Arora, Vivek K, Bolzenius, Jennifer, Bowman, Gregory R, Chu, Clarence E, Halstead, Angela M, Kapadia, Chiraag D, Schriefer, Andrew, Wartman, Lukas D   +7 more
core   +2 more sources

The effects of pioglitazone, a PPARγ receptor agonist, on the abuse liability of oxycodone among nondependent opioid users [PDF]

, 2016
Aims: Activation of PPARγ by pioglitazone (PIO) has shown some efficacy in attenuating addictive-like responses in laboratory animals. The ability of PIO to alter the effects of opioids in humans has not been characterized in a controlled laboratory ...
Alonzo, Banks, Begelow, Beitner-Johnson, Berger, Bhargava, Bland, Bush, Bussiere, Carr, Chang, Cone, Cooper, de Guglielmo, de Guglielmo, Dhalla, Eisenstein, Eisenstein, Eisenstein, Eng, Ferguson, Fraser, Gagnon, Garrido, Gelinas, Gillies, Hopkins, Hutchinson, Hutchinson, Hutchinson, Jeanne M. Manubay, Jermaine D. Jones, Johnston, Katz, Kielian, Kreutzberg, Ledeboer, Levine, Maria A. Sullivan, Marie-Claire, Martin, Mellon, Moreno, Nakajima, Narita, Pacifici, Pelvig, Roberto Ciccocioppo, Sandra D. Comer, Sarruf, Shanthi Mogali, Song, SPSS, Stoll, Stopponi, Stopponi, Strain, Sweitzer, Tawfik, Tontonoz, Verena E. Metz, Verkhratsky, Walker, Walker, Walsh, Walsh, Watkins, Watkins, Wightman, Woods, Wybran, Zacny, Zacny, Zacny, Zhang   +74 more
core   +1 more source

The effect of 12 weeks regular physical activity and vitamin E in the treatment of non-alcoholic steatohepatitis: A pilot study [PDF]

, 2015
Background: Despite the prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), there was no treatment has been proven to be effective in these common diseases.
Eslami, L., Eslami, L., Isazadehfar, K., Karami, M., Nakhostinroohi, B., Rahmani-nia, F.   +5 more
core   +7 more sources